全文获取类型
收费全文 | 6679篇 |
免费 | 445篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 69篇 |
儿科学 | 219篇 |
妇产科学 | 81篇 |
基础医学 | 1009篇 |
口腔科学 | 174篇 |
临床医学 | 590篇 |
内科学 | 1957篇 |
皮肤病学 | 119篇 |
神经病学 | 416篇 |
特种医学 | 101篇 |
外科学 | 938篇 |
综合类 | 18篇 |
预防医学 | 446篇 |
眼科学 | 101篇 |
药学 | 405篇 |
中国医学 | 14篇 |
肿瘤学 | 487篇 |
出版年
2023年 | 49篇 |
2022年 | 91篇 |
2021年 | 232篇 |
2020年 | 112篇 |
2019年 | 210篇 |
2018年 | 222篇 |
2017年 | 142篇 |
2016年 | 150篇 |
2015年 | 193篇 |
2014年 | 249篇 |
2013年 | 280篇 |
2012年 | 470篇 |
2011年 | 470篇 |
2010年 | 272篇 |
2009年 | 262篇 |
2008年 | 398篇 |
2007年 | 392篇 |
2006年 | 404篇 |
2005年 | 368篇 |
2004年 | 318篇 |
2003年 | 326篇 |
2002年 | 314篇 |
2001年 | 152篇 |
2000年 | 170篇 |
1999年 | 165篇 |
1998年 | 54篇 |
1997年 | 35篇 |
1996年 | 43篇 |
1995年 | 28篇 |
1994年 | 27篇 |
1993年 | 25篇 |
1992年 | 56篇 |
1991年 | 66篇 |
1990年 | 57篇 |
1989年 | 34篇 |
1988年 | 37篇 |
1987年 | 41篇 |
1986年 | 35篇 |
1985年 | 24篇 |
1984年 | 16篇 |
1982年 | 8篇 |
1980年 | 13篇 |
1979年 | 16篇 |
1978年 | 13篇 |
1977年 | 12篇 |
1976年 | 15篇 |
1975年 | 7篇 |
1973年 | 9篇 |
1968年 | 8篇 |
1967年 | 9篇 |
排序方式: 共有7144条查询结果,搜索用时 187 毫秒
1.
Ignasi Esteban Carmen Pastor-Quiones Lorena Usero Montserrat Plana Felipe García Lorna Leal 《Viruses》2021,13(3)
Over 36 million people worldwide are infected with HIV. Antiretroviral therapy (ART) has proven to be highly effective to prevent HIV-1 transmission, clinical progression and death. Despite this success, the number of HIV-1 infected individuals continues increasing and ART should be taken for life. Therefore, there are two main priorities: the development of preventive vaccines to protect from HIV acquisition and achieve an efficient control of HIV infection in the absence of ART (functional cure). In this sense, in the last few years, there has been a broad interest in new and innovative approaches such as mRNA-based vaccines. RNA-based immunogens represent a promising alternative to conventional vaccines because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. Some mRNA-based vaccines platforms against infectious diseases have demonstrated encouraging results in animal models and humans. However, their application is still limited because the instability and inefficient in vivo delivery of mRNA. Immunogens, design, immunogenicity, chemical modifications on the molecule or the vaccine delivery methods are all crucial interventions for improvement. In this review we, will present the current knowledge and challenges in this research field. mRNA vaccines hold great promises as part of a combined strategy, for achieving HIV functional cure. 相似文献
2.
Iclea Rocha Gama Euclides Marinho Trindade-Filho Suzana Lima Oliveira Nassib Bezerra Bueno Isabelle Tenório Melo Cyro Rego Cabral-Junior Elenita M. Barros Jaqueline A. Galvão Wanessa S. Pereira Raphaela C. Ferreira Bruna R. Domingos Terezinha da Rocha Ataide 《Metabolic brain disease》2015,30(1):93-98
3.
4.
José A. Lorente Pablo Cardinal-Fernández Diego Muñoz Fernando Frutos-Vivar Arnaud W. Thille Carlos Jaramillo Aida Ballén-Barragán José M. Rodríguez Oscar Peñuelas Guillermo Ortiz José Blanco Bruno Valle Pinheiro Nicolás Nin María del Carmen Marin Andrés Esteban Taylor B. Thompson 《Intensive care medicine》2015,41(11):1921-1930
5.
6.
J M Esteban J A Kuhn B Felder J Y Wong H Battifora J D Beatty P M Wanek J E Shively 《Cancer research》1991,51(14):3802-3806
We have previously shown that the colon carcinoma (LS174T) xenografts that emerged shortly after radioimmunotherapy with 90Y-labeled anti-CEA monoclonal antibody (MAb) ZCE025 lacked significant expression of CEA in comparison with the untreated tumors. The present study was designed to establish if the immunophenotype of the treated tumors was the result of CEA specific therapy and if the effect was permanent. Athymic mice bearing LS174T tumors were treated either with 120 mu Ci of 90Y-ZCE025, an equal dose of 90Y-96.5 (nonspecific MAb), or received no treatment. When the treated tumors grew to approximately 1.5 cm in diameter (6 weeks after therapy), they were resected and aliquoted to be transplanted to other mice, plated in tissue culture, fixed in formalin, and homogenized for CEA quantitation. The procedure was repeated 3 times (a total of 4 months after treatment). The CEA content was evaluated 2 and 6 weeks after therapy and when the tumors were transplanted. We confirmed a 4-fold decrease of CEA in the resurgent tumors 6 weeks after specific 90Y-ZCE025 therapy, which was twice the decrease experienced by the tumors treated with nonspecific 90Y-96.5, indicating substantial and specific killing of CEA-expressing cells. The CEA content slowly but progressively increased with each new pass of the tumor in the mice, reaching approximately one-half the value of the controls at the end of the study. The resurgent tumors were also studied by immunohistochemistry with MAbs detecting different epitopes of CEA, keratin, TAG-72, and epithelial membrane antigen to evaluate possible additional immunophenotypic changes induced by radioimmunotherapy. Only the expression of TAG-72 (recognized by MAb B72.3) increased immediately after therapy, but it returned to the original levels by the end of the study. These results suggest that: (a) specific radioimmunotherapy with 90Y-ZCE025 selectively kills cells that express higher levels of CEA; (b) the immunophenotype of the surviving fraction of the tumor appears to slowly revert to its original form; and (c) other tumor markers unrelated to CEA can also be affected. These observations have important implications for the design of radioimmunotherapy trials. 相似文献
7.
David Jiménez Castro Gema Díaz David Martí Carlos Escobar Javier Ortega Sergio García-Rull Joaquin Picher Antonio Sueiro 《Blood coagulation & fibrinolysis》2007,18(2):173-177
This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism. Three hundred and eighty consecutive noncancer outpatients hospitalized with an episode of symptomatic pulmonary embolism selected treatment with acenocoumarol or enoxaparin at a dose of 1 mg/kg once daily after being informed of the type of administration and expected frequency of laboratory monitoring for both medicinal products. Endpoints were symptomatic recurrent thromboembolic events evaluated by standard objective testing, and a composite endpoint of recurrent venous thromboembolism, major bleeding, and death from any cause. One hundred and ninety-nine patients (52%) chose acenocoumarol therapy and 181 chose enoxaparin monotherapy. Four patients in the enoxaparin group (2.2%) and six patients in the acenocoumarol group (3%) had an objective thromboembolic recurrence (hazard ratio, 1.35; 95% confidence interval, 0.38-4.79; P = 0.64). Nine patients in the enoxaparin group (5.0%) had a hemorrhagic complication compared with 11 in the acenocoumarol group (5.5%) (P = 0.81). The hospital length of stay was shorter with enoxaparin compared with acenocoumarol (11 versus 16 days, P = 0.0001). Enoxaparin is as effective and safe as acenocoumarol in the secondary prevention of recurrent thromboembolic disease and is associated with shorter hospitalization. 相似文献
8.
Carmen Guillén Ponce María Pilar Garrido López María José Molina Garrido Gema Muñoz Molina Alfredo Carrato 《Clinical & translational oncology》2007,9(1):53-55
Pituitary metastases of solid tumours are infrequent, specially as a first manifestation. When they happen, they are usually
due to breast or lung cancer and are asymptomatic or produce diabetes insipidus. It is very strange that they produce hormonal
deficiency.
We present a case report of a bronchogenic adenocarcinoma in a 65-year-old man which began with panhypopituitarism, diabetes
insipidus and visual alterations. Magnetic resonance imaging revealed a large sellar mass, with clivus infiltration and invading
the right cavernous sinus. The biopsy result was adenocarcinoma metastases from lung cancer. 相似文献
9.
10.